- The document discusses the use of incretin-based therapies like DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes who are not achieving adequate glycemic control on oral medications alone.
- It presents guidelines that recommend starting with basal insulin for patients still above HbA1c targets on dual or triple oral therapy, and then considering adding mealtime insulin, GLP-1 RA, or continuing uptitration of basal insulin if still above targets.
- The case examples show patients started on basal insulin with good initial response but still above goal, so the document discusses options of further uptitrating basal, adding mealtime insulin, or switching to a GLP-1
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
Final Presentation for Block 6
Objectives:
Describe the mechanism of action, side-effects and counseling points for GLP-1 RA
Compare and contrast GLP-1 RA studies
Discuss the PIONEER-6 study and its implications to clinical practice
GLP-1 is an incretin (hormone that increases insulin secretion in response to a meal), which is a 30-amino acid peptide secreted in response to the oral ingestion of nutrients by intestinal L cells.
GLP-1 receptors (GLP-1R) are located in islet cells, central nervous system, and other organs. GLP-1 is metabolized by the enzyme dipeptidyl peptidase-4 (DPP-4).
Incretin effect is a phenomenon whereby a glucose load delivered orally produces a much greater insulin secretion than the same glucose load administered intravenously.
This presentation is an overview of the entire GLP-1 system, followed by an introduction to leveraging its therapeutic potential using GLP-1 analogues (Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide) and DPP-4 inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin).
Shashikiran Umakanth delivered this talk at Manipal on 30th November, 2015
Diabetes is often accompanied by high triglyceride and high cholesterol levels. Saroglitazar (Lipaglyn) is a novel molecule that not only reduces elevated TG levels; it also reduces blood glucose levels. This presentation by Dr Vivek Baliga discusses this novel molecule.
Dr. John Buse prepared useful practice aids pertaining to type 2 diabetes for this CME activity titled "An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Wm2VJw. CME credit will be available until June 12, 2020.
http://www.theheart.org/web_slides/1135309.do
A study on Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients (ADVANCE)
Final Presentation for Block 6
Objectives:
Describe the mechanism of action, side-effects and counseling points for GLP-1 RA
Compare and contrast GLP-1 RA studies
Discuss the PIONEER-6 study and its implications to clinical practice
GLP-1 is an incretin (hormone that increases insulin secretion in response to a meal), which is a 30-amino acid peptide secreted in response to the oral ingestion of nutrients by intestinal L cells.
GLP-1 receptors (GLP-1R) are located in islet cells, central nervous system, and other organs. GLP-1 is metabolized by the enzyme dipeptidyl peptidase-4 (DPP-4).
Incretin effect is a phenomenon whereby a glucose load delivered orally produces a much greater insulin secretion than the same glucose load administered intravenously.
This presentation is an overview of the entire GLP-1 system, followed by an introduction to leveraging its therapeutic potential using GLP-1 analogues (Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide) and DPP-4 inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin).
Shashikiran Umakanth delivered this talk at Manipal on 30th November, 2015
Diabetes is often accompanied by high triglyceride and high cholesterol levels. Saroglitazar (Lipaglyn) is a novel molecule that not only reduces elevated TG levels; it also reduces blood glucose levels. This presentation by Dr Vivek Baliga discusses this novel molecule.
Dr. John Buse prepared useful practice aids pertaining to type 2 diabetes for this CME activity titled "An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Wm2VJw. CME credit will be available until June 12, 2020.
http://www.theheart.org/web_slides/1135309.do
A study on Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients (ADVANCE)
On DPP-Inhibitor ,case study on Linagliptin,Safe and affective class of drug for Management of Type II Diabetes as Monotherapy and add on therapy with OHA and Insulin,It can be added to SGLT2 Inhibitor also.
In Silico Prescription of Anticancer Drugs Reveals Targeting OpportunitiesNuria Lopez-Bigas
Large efforts dedicated to sequence thousands of tumor genome/exomes are expected to lead to significant improvements of precision cancer medicine. However, high inter-tumor heterogeneity is a major obstacle in the road to develop an arsenal of targeted cancer drugs to treat most cancer patients. Therefore, it is critical to understand the current scope of anti-cancer targeted drugs for different tumor types in order to use them with the highest efficacy, and to define priorities for the development of new ones. We have developed a novel methodology to interpret the genomes of a cohort of tumor samples and to assess their therapeutic opportunities. Starting with somatic mutations detected across the cohort, the methodology identifies the driver genes, highlights those that dominate the clonal landscape of the tumors and determines their mode of action. It then does an in-silico prescription of approved and candidate targeted drugs to each patient in the cohort. The application of this approach to a cohort of 6795 cancer samples of 28 different tumor types showed that the fraction of patients that could benefit from prescribed FDA-approved drugs is strikingly small. Nevertheless, it improves significantly if repurposing opportunities are taken into consideration, with large differences between tumor types. In addition, we identify 80 therapeutically unexploited cancer genes, tightly bound by pre-clinical small molecules or potentially suitable for molecule binding. The resource created with this analysis is also intended to provide interpretation of newly sequenced cancer genomes and to design pan-cancer and tumor type specific sequencing panels for efficient early cancer detection and clinical insight.
More details at http://www.intogen.org
This Presentation Give You A brief Information About DPP4 And New Recommendations .This Presentation Guide You How To Treat Patients With Safety.
For Further Contact:03354999496
Case studies in the managment of type 2 diabetes NasserAljuhani
Case 1:Poorly controlled type 2 diabetes on triple oral therapies
Case 2:Morning hypoglycemia on premixed InsulinCase 3
Case 3:Newly diagnosed D.M Type1D.M or type 2 D.M ?
Intensification Options after basal Insulin RevisitedUsama Ragab
Intensification Options revisited
By Dr. Usama Ragab Youssif
Add an OAD
Add a short-acting insulin at mealtime
Switch to premixed insulins
Novel insulin combinations
Basal insulin/GLP-1 RA combinations
مدیریت و کنترل دیابت نوع دو (Management of diabetes)HalehChehrehgosha
این فایل جهت یادگیری بهتر دانشجویان پزشکی فراهم شده است.
دکتر هاله چهره گشا
فوق تخصص غدد و عضو هیات علمی دانشگاه ایران
بیمارستان حضرت رسول اکرم تهران
chehrehgosha.h@iums.ac.ir
DIABETES IS A PROGRESSIV DISEASE AND WE NEED TO STAY ONE STEP AHEAD OF THE DISEASE.WE HAVE TO TITRATE THE MEDICATIONS EVERY THREE MONTHS AND THE TIME IS NOT OUR FRIEND AS FAR AS THE MANAGEMENT OF DIABETES IS CONCERNED
Slide Presentation
Diabetes Melliuts Type 2 management basics are life style modifications followed by use of Metformin
What is the best and safest next pharmacologic choice
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
3. CASE
A 51 year old male patient with type 2 DM diagnosed 6 years ago
Currently on Metformin 1 gm bd , Gliclazide MR 90 mg daily
Other Rx: ASA , Atorvastatin 40 mg , Lisinopril 10 mg
Excellent compliance to diet plan , activity and medication intake
Glucose monitoring is above target
4. What kind of monitoring would you like to know ?
Fasting , Pre-meals and @ Bed time
Vs
Fasting , Post-meals and @ Bed time
5. Post-prandial
hyperglycaemia
Post-prandial
hyperglycaemia
contributes HbA1c ~1%
B=breakfast; L=lunch; D=dinner.
Adapted from Riddle MC. Diabetes Care. 1990;13:676-686.
Plasmaglucose(mg/dL)
300
200
100
0
Time of day (h)
6 12 18 24 6
Uncontrolled Diabetes HbA1c 8.5%
B
L
D
Normal
HbA1c ~5%
Basal Hyperglycaemia Contributes More to Increased
HbA1c Levels Than Does Post-prandial Hyperglycaemia
Basal hyperglycaemia
contributes ~2%
Fasting
hyperglycaemia
6.
7. Case # 1
With higher HbA1C :
Pre-meal glucose readings contribute more to
the HbA1C
With HbA1C closer to target ( ex: <8-8.5%)
Post-meal glucose readings contributes more to
the HbA1C value
9. Breakfast Lunch Dinner Bedtime
Before After Before After Before After
Day1 12.7 11.0 9.2 9.8
Day2 10.4 10 12.5 11.9
Day3 13.5 13.5 9.6 9.8
Day4 14.7 12.9 10.5
Day5 11.8 13 11.5 10.5
SMBG Record … your assessment ?
10. CASE
A 55 year old male patient with type 2 DM
On Metformin 1 gm bd , Gliclazide MR 90 mg daily
BP 128/78 , BMI 32 kg/m2
Labs:
HbA1c 9.7 %
Serum Cr 65 ( e-GFR 86 ml/minute )
Urinalysis : Hematuria ( > 2 urine samples: to Urology for evaluation )
11. CASE
A 55 year old male patient with type 2 DM
On Metformin 1 gm bd , Gliclazide MR 90 mg daily
BP 128/78 , BMI 32 kg/m2
Labs:
HbA1c 9.7 %
Serum Cr 65 ( e-GFR 86 ml/minute )
Urinalysis : Hematuria ( > 2 urine samples: to Urology for evaluation )
-What is next ?
-Patient wants to avoid injections !!
12.
13.
14. CASE
A 55 year old male patient with type 2 DM
On Metformin 1 gm bd , Gliclazide MR 90 mg daily
Labs :
HbA1c 9.7 % Serum Cr 65 ( e-GFR 86 ml/minute )
DPP4 inhibitor was added at full dose ( Sitagliptin 100 or Linagliptin 5mg …)
Wants to avoid injectable Rx.
15.
16. Pioglitazone use and risk of bladder cancer:
population based cohort study
What this study adds
The use of Pioglitazone was associated with an overall
63% increased risk of bladder cancer, with the risk
increasing with increasing duration of use and dose
HR 1.63 (95% CI 1.22 to 2.19)
The use of Rosiglitazone was not
Likely to be a drug specific and not a class effect
Marco Tuccori,et al ; BMJ 2016; 352 doi:
http://dx.doi.org/10.1136/bmj.i1541
(Published 30 March 2016)Cite this as: BMJ 2016;352:i1541
17. Breakfast Lunch Dinner Bedtime
Before After Before After Before After
Day1 11 11.0 9.2 9.8
Day2 10.4 10 10.3
Day3 9.5 11.2 10.6 10.5
Day4 11.9 10.8
Day5 11.0 13 11.5 9.5
SMBG on: MFN + SU + DPP4i 3 months later
18. CASE
A 51 year old male patient with type 2 DM ;
BMI 31kg/m2
On Metformin 1 gm bd , Gliclazide MR 90 mg daily & + DPP4 inhibitor
Labs 3 months late: HbA1c ( 9.7% to 9.1% )
Serum Cr 60 ( e-GFR 90 ml/minute )
So…3 oral agents at max doses … and still out of control ?
19. Type 2 DM
Medications Barriers
Efficacy Limits
Adverse Reaction
Hypoglycemia
Weight gain
GI side effects
PO / Injection / Frequency
Cost
20.
21.
22.
23. Case
A 55 year old male patient with type 2 DM ;
BMI 32kg/m2
On Metformin 1 gm bd , Gliclazide MR 90 mg daily & + DPP4 inhibitor
Labs 3 months late: HbA1c ( 9.7% >>> 9.1% )
Serum Cr 60 ( e-GFR 90 ml/minute )
Does this patient need insulin?
24.
25.
26. ADA/EASD position statement 2015
DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium-glucose
co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione
Inzucchi et al. Diabetes Care 2015;38:140−149
Metformin + basal insulin + mealtime insulin or GLP-1RA
Healthy eating, weight control, increased physical activity
Not at target
HbA1c after
~3 months
Dual
therapy
Triple
therapy
Metformin
Combination
injectable
therapy
Monothera
py
Not at target
after 3 months:
combination
therapy
with insulin
TZD
DPP-4i
GLP-1RA
Insulin
SU
SU
TZD
Insulin
DPP-4i
GLP-1
RA
SU
TZD
Insulin
Insulin
TZD
DPP-4i
GLP-
1RA
Not at target
HbA1c after
~3 months
TZD
SU
DPP-4i
GLP-1RA
Insulin
Diseaseprogression
SU
TZD
DPP-4i
Insulin
SGLT-2i
27. ADA/EASD position statement 2015
DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium-glucose
co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione
Inzucchi et al. Diabetes Care 2015;38:140−149
Metformin + basal insulin + mealtime insulin or GLP-1RA
Healthy eating, weight control, increased physical activity
Not at target
HbA1c after
~3 months
Dual
therapy
Triple
therapy
Metformin
Combination
injectable
therapy
Monothera
py
Not at target
after 3 months:
combination
therapy
with insulin
DPP-4i
SU
SU
TZD
Insulin
DPP-
4i
GLP-1
RA
SU
TZD
Insulin
Insulin
TZD
DPP-4i
GLP-
1RA
Not at target
HbA1c after
~3 months
TZD
SU
DPP-4i
GLP-1RA
Insulin
Diseaseprogression
SU
TZD
DPP-4i
Insulin
SGLT-2i
HbA1c
9.7%
to
9.1%
28. ADA/EASD position statement 2015
DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium-glucose
co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione
Inzucchi et al. Diabetes Care 2015;38:140−149
Basal insulin
Healthy eating, weight control, increased physical activity
Not at target
HbA1c after
~3 months
Dual
therapy
Triple
therapy
Metformin
Combination
injectable
therapy
Monothera
py
Not at target
after 3 months:
combination
therapy
with insulin
DPP-4i
SU
SU
TZD
Insulin
DPP-
4i
GLP-1
RA
SU
TZD
Insulin
Insulin
TZD
DPP-4i
GLP-
1RA
Not at target
HbA1c after
~3 months
TZD
SU
DPP-4i
GLP-
1RA
Insulin
Diseaseprogression
SU
TZD
DPP-4i
Insulin
SGLT-2i
29. Case # 1
Basal insulin
Effective
Easy choice : single injection /Pen
(at bedtime)
“Breaks the Ice”
31. Case # Basal Insulin
Example: body weight 0f 80 kg
16-24 units (0.2-0.3 u/kg) of
Glargine or Detemir added at Bedtime
Degludec ;flexible time
Or
Start a dose of 10 units
Titrate every 2-3 days
32. SA- GLA-11-11-04
32
In T2DM ‘Fix fasting first’ –will lower the entire plasma
glucose through 24 hr
Adapted from Polonsky K. N Engl J Med 1988;318:1231–9 and Hirsch I, et al. Clin Diabetes 2005;23:78–86.
Theoretical simulation of diurnal blood glucose profile
Time of day (hours)
400
300
200
100
0
06:00 06:0010:00 14:00 18:00 22:00 02:00
Plasmaglucose(mg/dL)
Normal
Meal Meal Meal
20
15
10
5
0
Plasmaglucose(mmol/L)
Hyperglycaemia due to an increase in fasting glucose
T2DM
33. Breakfast Lunch Dinner Bedtime
Before After Before After Before After
Day1 10 11.0 10.2 10
Day2 7.4 9.0 9.3
Day3 6.5 9.2 11.0 11
Day4 9.9 11.8
Day5 7.2 11 11.0 10.5
After add on Glargine /Detemir 24 units HS>> 40 u
34. SA- GLA-11-11-04
When Basal Insulin is “Not Enough”
• Step 1: Think first of titrating the basal insulin dose till reaching
FBG target (Often under-dosage) ; Max 0.5 units /kg
• Step 2: Shift to Basal Plus or Basal-bolus (MDI) regimen :
• Number of daily injections up to 4 (1+3)
• Inconvenience
• Risk of hypoglycemia & Weight gain
Or
Incretin-Based Rx
35. ADA/EASD position statement 2015
DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium-glucose
co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione
Inzucchi et al. Diabetes Care 2015;38:140−149
Basal insulin
Healthy eating, weight control, increased physical activity
Not at target
HbA1c after
~3 months
Dual
therapy
Triple
therapy
Metformin
Combination
injectable
therapy
Monothera
py
Not at target
after 3 months:
combination
therapy
with insulin
DPP-4i
SU
SU
TZD
Insulin
DPP-
4i
GLP-1
RA
SU
TZD
Insulin
Insulin
TZD
DPP-4i
GLP-
1RA
Not at target
HbA1c after
~3 months
TZD
SU
DPP-4i
GLP-
1RA
Insulin
Diseaseprogression
SU
TZD
DPP-4i
Insulin
SGLT-2i
HbA1c
9.1
to
8.0%
36. ADA/EASD position statement 2015
DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium-glucose
co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione
Inzucchi et al. Diabetes Care 2015;38:140−149
Basal insulin + Meal Related Insulin
Healthy eating, weight control, increased physical activity
Not at target
HbA1c after
~3 months
Dual
therapy
Triple
therapy
Metformin
Combination
injectable
therapy
Monothera
py
Not at target
after 3 months:
combination
therapy
with insulin
DPP-4i
SU
SU
TZD
Insulin
DPP-
4i
GLP-1
RA
SU
TZD
Insulin
Insulin
TZD
DPP-4i
GLP-
1RA
Not at target
HbA1c after
~3 months
TZD
SU
DPP-4i
GLP-
1RA
Insulin
Diseaseprogression
SU
TZD
DPP-4i
Insulin
SGLT-2i
37. ADA/EASD position statement 2015
DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2i, sodium-glucose
co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione
Inzucchi et al. Diabetes Care 2015;38:140−149
Basal Insulin + GLP 1 RA
Healthy eating, weight control, increased physical activity
Not at target
HbA1c after
~3 months
Dual
therapy
Triple
therapy
Metformin
Combination
injectable
therapy
Monothera
py
Not at target
after 3 months:
combination
therapy
with insulin
SU
DPP-4i
GLP-
1RA
Insulin
SU
SU
TZD
Insulin
DPP-
4i
GLP-1
RA
SU
TZD
Insulin
Insulin
TZD
DPP-4i
GLP-
1RA
Not at target
HbA1c after
~3 months
TZD
SU
DPP-4i
GLP-
1RA
Insulin
Diseaseprogression
SU
TZD
DPP-4i
Insulin
SGLT-2i
38.
39. Mechanism of action of GLP-1RAs and DPP-4
inhibitors
Food
Gut
Food-activated
GLP-1 response
The enzyme DPP-4
breaks down GLP-1
GLP-1RAs work like
natural GLP-1 and are
DPP-4-resistant
DPP-4
GLP-1R
Glucose-dependent insulin
secretion
Beta cell
DPP-4 inhibitors act to
block the DPP-4 enzyme
40. Additional physiological benefits are observed at pharmacological
levels of GLP-1
DPP-4is, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide 1; GLP-1RAs, glucagon-like peptide 1 receptor agonists
Adapted from Holst et al.1
1. Holst JJ et al. Trends Mol Med 2008;14:161–168; 2. Flint A et al. Adv Ther 2011;28:213–226
Gastric
emptying
Physiological
GLP-1 levels
Pharmacological
GLP-1 levels
GLP-1 effects
IncreasingplasmaGLP-1
concentrations
GLP-1RAs
DPP-4is
Insulin
Glucagon
= Plasma glucose2
Appetite
Food intake
= Weight loss2
41. The Incretin Therapy
Short Acting
– Exenatide bid
Lixisenatide OD
Long Acting:
Liraglutide
Exenatide LAR
Dulaglutide
Albiglutide
(Semaglutide)
Incretin mimetics: GLP-1 receptor agonists
Stable peptide analogues of GLP-1
– Post-Prandial Glucose – Fasting Glucose
42. GLP-1RA vs. DPP-4 inhibitor: change in HbA1c
Data are LS mean. *p<0.0001 vs. sitagliptin; †p=0.01 vs. liraglutide 1.2 mg
Pratley et al. Int J Clin Pract 2011;65:397–407; Bergenstal et al. Lancet 2010;376:431–9
Baseline HbA1c:
LIRA–DPP-4i (52 weeks)
ChangeinHbA1c(%)
p<0.0001
p<0.0001
ADA target
(<7.0%)
27% 50%* 63%*†
DURATION-2 (26 weeks)
ChangeinHbA1c(%)
p<0.0001
Sitagliptin
100 mg OD
Exenatide
2 mg OW
Sitagliptin
100 mg OD
Liraglutide
1.2 mg OD
Liraglutide
1.8 mg OD
Baseline HbA1c: 8.5% 8.6% 8.5% 8.4% 8.4%
~30% ~58%*
43. GLP-1RA vs. DPP-4 inhibitor: change in body weight
Changeinbodyweight(kg)
p<0.0001
p<0.0001
Data are LS mean
Pratley et al. Int J Clin Pract 2011;65:397–407; Bergenstal et al. Lancet 2010;376:431–9
Changeinbodyweight(kg)
p=0.0002
Baseline
body weight: 87 kg 89 kg 93 kg 94 kg 95 kg
LIRA–DPP-4i (52 weeks)DURATION-2 (26 weeks)
Sitagliptin
100 mg OD
Exenatide
2 mg OW
Sitagliptin
100 mg OD
Liraglutide
1.2 mg OD
Liraglutide
1.8 mg OD
44. DURATION-2: safety and tolerability from Week 0 to
Week 26
Bergenstal et al. Lancet 2010;376;431–9; Bydureon. EMA: Summary of Product Characteristics. 2011;
available from: http://www.medicines.org.uk/emc/medicine/24665/SPC/ (accessed 2 November 2011)
0
5
10
15
20
25
30
35
40
Exenatide OW (100 mg) Sitagliptin (100 mg)
Adverseevents(%)
Nausea Diarrhoea Vomiting Injection site pruritis
• Incidence of minor hypoglycaemia was low and similar between
groups (1–3%)
• Nausea was predominantly mild
45. Switching from DPP-4 inhibitor to a GLP-1RA: change in
HbA1c
Data are LS mean. †Mean HbA1c at week 26 for all core study participants; *p<0.05 for change from switch
Pratley et al. Diabetes Care 2012;DOI:10.2337/dc11-2113; Wysham et al. Diabetic Medicine 2011;28:705–14
LIRA–DPP-4i
(Weeks 52–78)
ChangeinHbA1c(%)
p=0.006
p=0.0001
ADA target HbA1c
<7.0%
DURATION-2
(Weeks 26–52)
ChangeinHbA1c(%)
p=0.001
Week 26 HbA1c:
7.2% 7.6%
Week 52 HbA1c:
7.6%†
Sitalira 1.2 mg
Sitalira 1.8 mgSitaexenatide OW
50%*
30%30%
49%*
36%
53%*
46. Switching from a DPP-4 inhibitor to a GLP-1RA: change in body
weight
LIRA–DPP-4i
(Weeks 52–78)
Changeinbodyweight(kg)
p<0.0001
p<0.0001
Changeinbodyweight(kg)
p=0.0006
Week 26
body weight: 92.8 kg 91.6 kg
Week 52
body weight:
86 kg†
Sitalira 1.2 mg
Sitalira 1.8 mgSitaexenatide OW
Data are LS mean. †Mean body weight at week 26 for all core study participants
Pratley et al. Diabetes Care 2012;DOI:10.2337/dc11-2113; Wysham et al. Diabetic Medicine 2011;28:705–14
DURATION-2
(Weeks 26–52)
53. 53
Study Design
Entry Criteria:
• T2DM HbA1c >7.0 to ≤10%
• IG + MET with or w/o SU*
• IG ≥20 IU/day
*SU, sulfonylurea discontinued upon study entry; MET, metformin
1. Yki-Jarvinen H, et al. Diabetes Care. 2007;30:1364-1369; 2. Rosenstock J, al. Diabetes Care. 2008;31:20-25.
Week
Basal Insulin Optimization (BIO)
Titrated Basal IG1
12-wk BIO Phase
0 30
30-wk Intervention Phase
Ex-BID 5mg Ex-BID 10mg
LisTID2
Titrated Basal IG1
+ MET continued throughout study
Randomization
-12-14
Screening
Michaela Diamant, Diabetes Care 2014;37:2763–2773
54. 54
Titration of Basal Insulin Glargine Once Daily
( IG QD), Byetta and Prandial Lispro TID
Target fasting glucose <5.6 mmol/L (<100 mg/dL) with no hypoglycemia
BIO-phase: IG QD1
Lis TID2
Target pre-prandial glucose <6.1 mmol/L
(<109mg/dL) with no hypoglycemia
ExBID
Dose increased at wk 4 and tapered
thereafter if side-effects occurred
Target fasting glucose <5.6 mmol/L (<100 mg/dL) with no hypoglycemia
Intervention phase: IG QD1
ExBID+IG arm
IG decreased by ≥10% if HbA1c ≤8.0% &
at wk 4 with ExBID dose↑
LisTID+IG arm
½ up to ⅔ of IG daily dose maintained,
⅓- ½ divided into 3 pre-meal doses of Lis
At Randomization
Michaela Diamant, Diabetes Care 2014;37:2763–2773
55. 55
Results: HbA1c at 30 Weeks
Values are LS Mean ± SE calculated using MMRM; *N’s for target achievement are patients with HbA1c values at 30 wk
Michaela Diamant, Diabetes Care 2014;37:2763–2773
56. 56
Results: Fasting and Self-Measured Glucose
Per protocol population (N=510), Fasting glucose values are LS Mean ± SE; blood glucose values are Mean ± SE; *P<0.0001
Michaela Diamant, Diabetes Care 2014;37:2763–2773
57. 57
Results: Mean Daily Insulin Doses
Per protocol population (N=510), Values are Mean ± SD
Michaela Diamant, Diabetes Care 2014;37:2763–2773
59. 59
Results: Incidence of Hypoglycemia
Overall Rate per patient-year (Minor and Major): 2.1 (ExBID + IG) vs. 5.1 (LisTID + IG)
Michaela Diamant, Diabetes Care 2014;37:2763–2773
Conclusions:
Adding Exenatide to titrated Glargine with Metformin
resulted in similar glycemic control as add on Lispro insulin
GLP1- RA (Exenatide) is a safe, effective and well tolerated
non insulin Rx if Basal insulin fails
63. Compared with DPP-4 inhibitors, GLP-1 RA are associated with:
1-Greater HbA1c reduction and greater weight loss
2-Similar low risk of hypo-glycaemia but
an increased incidence of gastrointestinal events
Switching from a DPP-4 i to a GLP-1 RA was associated with:
1-Significant additional HbA1c reductions
2-Significant weight loss
64. Incretins based therapy ( DPP4 I and GLP1-RA) provides an
excellent combination with Insulin :Basal and MDI
GLP1-RA is an excellent effective alternative to
meal related insulin on top of basal insulin with:
-Equal postprandial efficacy
-Same or better HbA1c lowering and
-Same /lower risk of hypoglycemia
- Weight loss